Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.
…
continue reading
Talking Biotech is a weekly podcast that uncovers the stories, ideas and research of people at the frontier of biology and engineering. Each episode explores how science and technology will transform agriculture, protect the environment, and feed 10 billion people by 2050. Interviews are led by Dr. Kevin Folta, a professor of molecular biology and genomics.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Redefining Dementia Care: CervoMed's Bold Journey with CEO John Alam
24:38
24:38
Play later
Play later
Lists
Like
Liked
24:38
Get ready for an insightful conversation as Rahul Chaturvedi connects with John Alam, CEO of CervoMed, to uncover the revolutionary advancements transforming dementia treatment, with a spotlight on Dementia with Lewy Bodies (DLB). John shares his remarkable journey from practicing medicine to leading cutting-edge biotech innovations, shedding light…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The GMO Tree You Never Heard About - Dr. Chris Dardick, USDA/ARS
34:14
34:14
Play later
Play later
Lists
Like
Liked
34:14
We regularly discuss a small suite of commercial crops that have been genetically enhanced with transgenes. However, one additional genotype was transformed long ago, and approved for use in the USA, Canada and EU-- but nobody talks about it much. It is the plum resistant to plum pox virus (PPV), a devastating virus of stonefruits. While rare in th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Anti-GMO Hawaii Memories; A Career in Ag Science - Dr. Steve Savage
59:17
59:17
Play later
Play later
Lists
Like
Liked
59:17
In 2013 a number of county ordinances sought to end the use of biotech crops on various Hawaiian islands. Hawaii's warm year-'round climate permits several corn seasons a year, so seed corn for the mainland is produced in these locations. However, these technologies are not appreciated by a subset of the population, who see these companies as poiso…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
From Banking to Biotech: Renée Aguiar-Lucander, CEO of Calliditas, on Rare Disease Innovation
30:51
30:51
Play later
Play later
Lists
Like
Liked
30:51
Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, appears on this insightful episode of Biotech 2050 with host Rahul Chaturvedi. Renée shares her unconventional journey from investment banking to biotech leadership, underscoring the crucial role of capital markets and regulatory strategies. The discussion explores the unique challenges of deve…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Enabling Local Production of Protein Therapeutics - Dr. Kerry Love, Sunflower Therapeutics
34:53
34:53
Play later
Play later
Lists
Like
Liked
34:53
Great products and ideas are everywhere, yet limited by the ability to actually produce them in needed quantitites. The technologies from Sunflower Therapeutics enable bioprocess applications throughout the globe in a deployable unit with a small footprint. Dr. Kerry Love describes the technology and it's applications, along with the philosophy of …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Autoimmune Innovations: Insights from Marshall Fordyce, Founder & CEO, Vera Therapeutics on Biotech
32:50
32:50
Play later
Play later
Lists
Like
Liked
32:50
Synopsis: In this engaging episode, host, Rahul Chaturvedi welcomes Marshall Fordyce, Founder and CEO of Vera Therapeutics, to discuss his transformative journey from physician to biotech entrepreneur. Marshall shares the story behind Vera Therapeutics' strategic pivot to focus on IG nephropathy and their development of atacicept, a promising B-cel…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Measuring the Health of T-Cells - Dr. Nigel McCracken, Virax Biolabs
50:35
50:35
Play later
Play later
Lists
Like
Liked
50:35
T-cells are a critical part of the adaptive immune system, actively targeting problematic invaders. From pathogens to cancers, T-cells seek and destroy potentially dangerous cells, and maintain a memory of their presence. In today's episode Dr. Nigel McCracken describes this part of the adaptive immune system and how Virax Biolabs is using speciali…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Transforming Gene Therapy: Exclusive Insights from Zandy Forbes, President & CEO of MeiraGTx
50:25
50:25
Play later
Play later
Lists
Like
Liked
50:25
Zandy Forbes, Founder, President, and CEO of MeiraGTx, joins host Rahul Chaturvedi in this compelling episode. Zandy shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company. She elabor…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Resistance to Correction, Breaking Trust in Science - Drs. Andrea Love and Nicole Keller
44:04
44:04
Play later
Play later
Lists
Like
Liked
44:04
Disinformation clouds the public understanding of science, especially technology in agriculture and medicine. So when a leading journal publishes false information, academic experts have an obligation to help correct the process. This may be done via a variety of methods, but cordial and collegial discussion is the first step. When that fails, note…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Biotech Breakthroughs: Jeb Keiper, CEO of Nimbus Therapeutics, Discusses Their Innovative Journey
35:03
35:03
Play later
Play later
Lists
Like
Liked
35:03
Dive into this episode of Biotech 2050 where host Rahul Chaturvedi interviews Jeb Keiper, CEO of Nimbus Therapeutics. Discover Jeb's fascinating journey from MIT chemist to industry leader, and the unique strategies that have driven Nimbus's success. Jeb discusses the evolution of biotech financing, the importance of taking bold risks, and the inno…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Revolutionizing Proteomics: Sujal Patel, Co-Founder & CEO of Nautilus, on Drug Development
36:55
36:55
Play later
Play later
Lists
Like
Liked
36:55
Sujal Patel, co-founder and CEO of Nautilus Biotechnology, discusses their innovative work in proteomics and its impact on drug development. Sujal shares his transition from tech to biotech, the formation of Nautilus with Parag Mallick, and their revolutionary approach using multi-affinity probes. The conversation highlights the importance of prote…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Your Role in Editing Wikipedia - Susan Gerbic
42:32
42:32
Play later
Play later
Lists
Like
Liked
42:32
Wikipedia is the go-to source for many people when starting to research a subject. But is the information correct, or does the information even exist in Wikipedia at all? Susan Gerbic has been training people to edit Wikipedia pages through the Gorilla Skeptics of Wikipedia project. They have edited tens of thousands of pages with over 16 million v…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Gene Editing in Specialty Crops - Dr. Tom Adams, CEO Pairwise
32:06
32:06
Play later
Play later
Lists
Like
Liked
32:06
Crop genetic engineering has focused primarily on large-acreage crops like corn. But what about the universe of specialty crops that tantalize consumers, things like blackberries or salad greens? Pairwise has used precision twists on gene editing to change specific traits in fruit and vegetable crops. Pairwise founder and CEO, Dr. Tom Adams, discus…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Special Panel - From Pre-Clinical to Clinical Trials
33:33
33:33
Play later
Play later
Lists
Like
Liked
33:33
Advancement of a new drug from pre-clinical trials to clinical trials is a pivotal time in validation of its therapeutic effects and safety. A panel of experts discusses the process.By Colabra
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Exploring Neuroscience, Psychiatry, & Rare Diseases, Bruce Leuchter, President & CEO, Neurvati
51:22
51:22
Play later
Play later
Lists
Like
Liked
51:22
Synopsis: In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of Vibe Bio, speaks with Dr. Bruce Leuchter, President and CEO of Neurvati Neuroscience. They discuss capital markets, neurology, psychiatry, and Neurvati's work in ultra-rare diseases. Dr. Leuchter shares his journey from clinical training to leadership at Neurvati. The …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Talking Biotech Begins Year 10! with Dr. Liza Dunn
1:03:32
1:03:32
Play later
Play later
Lists
Like
Liked
1:03:32
Today's episode marks the beginning of the 10th year of the Talking Biotech Podcast. To celebrate, Drs. Liza Dunn and Kevin Folta discuss the last decade of biotech breakthroughs and communications efforts, the fight against technology and the amazing progress in gene editing and human genetic therapies. Plus, what you can do to help the effort goi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Transformative Oncology Innovations, Ken Keller, President & CEO, Daiichi Sankyo, Inc.
28:18
28:18
Play later
Play later
Lists
Like
Liked
28:18
Synopsis: In this episode of BioTech 2050, Ken Keller, President and CEO of Daiichi Sankyo, Inc. provides an in-depth look into the company's transformation from a cardiovascular-focused organization to a leader in oncology. He discusses the groundbreaking advancements in antibody-drug conjugates (ADCs), particularly highlighting the success of the…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Targeting Chronic Inflammation Via the Inflamasome - Dr. David Bearss
47:33
47:33
Play later
Play later
Lists
Like
Liked
47:33
Chronic inflammation goes hand-in-hand with many diseases, complicating symptoms and affecting routes of treatment. What is the molecular basis of inflammation, and can it be targeted by new drugs? Scientists have studied the molecular basis of the inflammatory response and have identified specific proteins that complex to initiate the response. Ne…
…
continue reading
Strategic partnerships are becoming more important in development and deployment of biotechnology solutions. Today's panel discusses the way partnerships are formed, some of the important considerations with IP and licensing, and how relationships are managed.By Colabra
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Strategic Leadership and Autoimmune Breakthroughs, Praveen Tipimeni, CEO
34:03
34:03
Play later
Play later
Lists
Like
Liked
34:03
Synopsis: In this episode of Biotech2050, Praveen Tipirneni, CEO of Morphic Therapeutics, shares insights on Morphic’s strategic IPO, the rising interest in autoimmune treatments, the journey of their alpha 4 beta 7 program, and maintaining a conservative yet opportunistic approach in biotech. He also discusses the importance of building a strong t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Journal Club - Were "High Levels" of Glyphosate Found in Sperm? - Dr. Andrea Love
27:59
27:59
Play later
Play later
Lists
Like
Liked
27:59
The news reports say that scientists have found "high levels" of herbicide in human sperm, and suggest it is a cause of infertility. But what do the data really say? Dr. Andrea Love and I discuss the paper. A report by Vasseur et al., in the June 2024 Ecotoxicology and Environmental Safety entitled Glyphosate presence in human sperm: First report a…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Standardizing Therapeutic Protein Production in Plants - Jim Wilson
47:53
47:53
Play later
Play later
Lists
Like
Liked
47:53
Where many therapeutic compounds are raised in bacteria or fungi, plants sometimes offer many advantages as bioreactors. Capital and production costs are lower, and products may be edible instead of injectable. The problem tends to be standardization, and conditions that ensure that the desired proteins are produced This episode features Jim Wilson…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Innovative Approaches to Cancer Therapies, Robert Ang, President and CEO
30:09
30:09
Play later
Play later
Lists
Like
Liked
30:09
Synopsis: In this episode of BioTech 2050, Robert Ang, CEO of Vor Bio, shares insights on the current state of cancer therapies and next-gen modalities. He discusses Vor Bio's work on shielded stem cell transplants and CAR T-cell therapies targeting hematologic malignancies like AML and MDS. Robert also talks about his experience serving on boards …
…
continue reading
![Artwork](/static/images/128pixel.png)
51
Canadian Rules for Gene Editing - Jennifer Hubert
27:00
27:00
Play later
Play later
Lists
Like
Liked
27:00
Canada has a unique approach to plant genetic improvement that follows the product, not the process. In other words, if there is potential risk from any genetic manipulation technique, from polyploidization to transgenic to gene edits, Canadian regulators assess the relative risk in the final product. But what does the regulatory climate look like …
…
continue reading